CEO Presentation
Released
Released
Announcement PDF
NOVEMBER 2023
www.avecho.com.au
| ASX:AVE
SAFE HARBOUR STATEMENT
AVECHO BIOTECHNOLOGY
This presentation, and any representations made before, during or after the presentation, may include forwardlooking statements that are inherently subject to risks and uncertainties. These statements relate to, but are not
limited to: (1) the safety or efficacy of, or potential applications for, Avecho’s TPM® platform technology; (2) the
strength of Avecho‘s intellectual property; (3) the timelines for Avecho’s clinical trials and regulatory processes for its
different products; (4) the scalability and efficiency of manufacturing processes; (5) revenue projections, market
share expectations, share price expectations and capital requirements.
Actual results may differ from the expectations expressed in these forward-looking statements, and the differences
may be material (whether positive or negative). The risks that may cause Avecho‘s actual results, performance or
achievements to be materially different from those expressed or implied by such forward-looking statements, include
but are not limited to: (1) risks inherent in the development, approval and commercialization of potential products;
(2) uncertainty of clinical trial results or regulatory approvals or clearances; (3) changes to market trends or
government laws or regulations; (4) the potential need for future capital; (5) dependence upon collaborators; and
(6) protection of intellectual property rights, among others. Accordingly, you should not place undue reliance on
these forward-looking statements.
May 2022
AVECHO BIOTECHNOLOGY
November 2023
2
2
CLEAR STRATEGIC FOCUS
1. Complete pivotal Phase III clinical trial for
CBD capsule containing TPM® technology
2. License this and other TPM cannabinoid
products into lucrative global markets
May 2022
AVECHO BIOTECHNOLOGY
November 2023
3
3
COMPANY SNAPSHOT
Board and Management Team
AVE Corporate Summary1
Total shares (including T2)
3.17 Bn
Total options (including T2)2
2.37 Bn
Cash (end Q3 2023)
A$4.74 M
+ T2
A$2.80 M
MCAP3
Dr Paul Gavin
Chief Executive Officer
- 20+ years Avecho, PhD Biochemistry
- Ex-AVE CSO, Inventor of TPM platform
- Ran pharmaceutical development programs from
concept to licensing
Dr Roksan Libinaki
Chief Operating Officer
- 20+ years Avecho. PhD Biochem, Exec MBA
- Company operations and clinical trials
- Ran nutraceutical, animal health and
manufacturing business units at Avecho
Melanie Leydin
Chief Financial Officer & Co. Sec
- 25+yrs accounting
- 15+ yrs Co-Sec − Inst. of Chartered Accts
- MD Vistra Australia
Dr Greg Collier
Chairman
- 25+yrs biotech exec experience
- Sold (as CEO) Chemgenex ($200M+); one of
the biggest Biotech exists in Australian history
- 150 scientific publications, 33 scientific patents
Dr Ross Murdoch
Non-Executive Director
- 25+yrs biotech/Big Pharma exec experience
- CEO of Extractas, Australia’s largest cannabis
grower/extractor
- ex Shire Pharma, Glaxo, Astra-Zeneca.
Matt McNamara
Non-Executive Director
- 30+yrs healthcare, 20+yr venture capital
- Director/CIO Horizon 3 Healthcare
- Previous CIO BioScience Managers, CEO
SciCapital, Merck & Co
A$10.79 M
1 Assuming shareholder approval of all EGM resolutions
2 Various exercise price and expiry dates
3 As of 7th November 2023
May 2022
AVECHO BIOTECHNOLOGY
November 2023
4
4
THE GLOBAL CANNABIS MARKET IS ALREADY HUGE
Global Legal Cannabis Market1
•
Legal use (medicinal or adult) in 30 countries
•
Valued at $17.8 billion USD in 2021
•
65.0% of the market in North America in 2021
•
Projected compound annual growth rate (CAGR) of 25.3%
•
Expected to reach $73.6 billion USD by 2027
Australian Cannabis Market2
•
Medicinal use only
•
$66 million USD in 2022
•
Expected to reach $540.6 million USD by 2030
•
Projected CAGR of 30.1%
Despite the global
value of the
cannabis market, the
products have
become commodities
with little
commercial
differentiation
Sources:
1. https://www.grandviewresearch.com/industry-analysis/legal-cannabis-market
2. https://www.researchandmarkets.com/reports/5450192/australia-legal-cannabis-market-size-share-and
May 2022
AVECHO BIOTECHNOLOGY
November 2023
5
5
THE PROBLEM WITH CANNABINOIDS
Cannabinoids have very poor oral bioavailability; only
~6% of ingested cannabinoids are absorbed
Avecho’s TPM increases oral CBD absorption
Increasing cannabinoid absorption has become a focus
for many laboratories around the world
Increasing bioavailability can allow;
Greater therapeutic effect
New indications, previously untreatable because of
high doses required
Reduced dosing for cost savings to patients
Provide commercial differentiation
Few medicinal cannabis companies have the expertise to
address these issues
May 2022
AVECHO BIOTECHNOLOGY
November 2023
• Single oral dose of Epidiolex (FDA approved CBD oil) or Epidiolex +
TPM administered to dogs
• Blood collected over time and the amount of CBD in blood quantified
6
6
PHARMACEUTICAL CANNABIDIOL IS VALUABLE
Only one pharmaceutical CBD product is approved by the FDA (Epidiolex®)1
•
Epidiolex was developed by GW Pharma
•
Approved for rare childhood epilepsy conditions2 – rarely prescribed
•
GW Pharma was acquired for $7.2Bn USD by Jazz Pharma (2021) to
obtain Epidiolex3
•
It is anticipated that registered pharmaceutical CBD products
for broader indications would be more valuable
Avecho is targeting large indications such as insomnia for its
pharmaceutical CBD product – large commercial opportunity
Sources:
1. https://www.epidiolex.com/
2. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms
3. https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-acquire-gw-pharmaceuticals-plc-creating
May 2022
AVECHO BIOTECHNOLOGY
November 2023
7
7
INSOMNIA IN AUSTRALIA – UNIQUE CBD OPPORTUNITY
Insomnia can be broadly defined as difficulty initiating or
maintaining sleep
The TGA allows CBD products to be registered as over-thecounter (OTC) medicines1 for indications such as insomnia
OTC medicines are available direct from a pharmacist without
a prescription, a significant commercial advantage
Australians spend $5B per year on OTC medicines2
No pharmaceutical CBD products are approved for
sleep, but insomnia remains one of the most prevalent
indications targeted globally by medical cannabis and
consumer CBD products3
Avecho is well placed to be one of the
first to achieve OTC TGA registration
•
40% of Australians getting less sleep than they need
•
59.4% Experience symptoms 3-4 times per week
•
Only 20% report their sleep is uninterrupted
•
Costs Australian economy $19.1 B per annum
•
Australian insomnia market ~$250M per annum
•
Global insomnia market >$4B per annum
https://www.deloitte.com/au/en/services/economics/analysis/rise-try-to-shine.html
Sources:
1. https://www.tga.gov.au/news/media-releases/over-counter-access-low-dose-cannabidiol
2. Medicines in the health system, Australian Institute of Health and Welfare (2022)
3. Suraev, A.S., et al.. Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. Sleep Medicine Reviews 2020b (53); 101339.
May 2022
AVECHO BIOTECHNOLOGY
November 2023
8
8
PHASE III STUDY DESIGN
Based upon study design from FDA approved insomnia medications
Assessments include;
Avecho’s Phase III insomnia trial has been
designed to maximise the chance of success.
Compared to recent studies, Avecho’s trial uses;
•
The maximum dose (150mg)
•
Larger patient numbers (540 patients)
•
Higher insomnia scores required for inclusion
•
Longer dosing period (8 weeks)
•
An interim analysis (after 200 patients) to
calculate required patient numbers
•
Methods to minimise the placebo effect
May 2022
AVECHO BIOTECHNOLOGY
November 2023
•
Daily sleep diary to record nightly sleep.
•
Sleep questionnaire every two weeks.
•
Wearable device to record daily objective sleep data
•
Secondary endpoints related to anxiety
8 week treatment period
Treatment A – Placebo before bed
Treatment B – 75 mg CBD before bed
Treatment C – 150 mg CBD before bed
9
9
TIMELINES TO INTERIM ANALYSIS - MAJOR GO/NO GO
2023
Jan Feb
Mar
Apr May Jun
Jul
2024
Aug Sep
Oct Nov
Dec Jan Feb
Mar
Apr May Jun
Jul
Aug Sep
Oct Nov
Dec
Funding Activities
Manufacturing
Activities
Clinical supply
Registration batches
Stability
Phase III Trial
Results
Interim
Analysis
Database build
Patient recruitment
Dosing patients
Interim Analysis
GO/NO GO
Licensing
discussions
May 2022
AVECHO BIOTECHNOLOGY
November 2023
10
10
VALUE DRIVERS
•
Proprietary cannabinoid portfolio differentiated with TPM delivery technology
•
Pivotal Phase III trial for an insomnia indication ready to go
•
•
Dosing to commence early 2024 – Interim analysis Q3/Q4
CBD capsule targeting over-the-counter registration in Australia, followed by ROW
•
Huge potential commercial opportunity – competitor studies all failed their primary endpoints
•
Further clinical trials being conducted on CBD capsule, funded by third parties
•
Further cannabinoid products under investigation (gels, oils, edibles)
•
Partnerships for non-cannabinoids products (Perrigo, Arthur Group)
May 2022
AVECHO BIOTECHNOLOGY
November 2023
11
11
QUESTIONS WELCOME
Dr Paul Gavin
Chief Executive Officer
T. +61 3 9002 5000
E. pgavin@avecho.com.au
Melbourne Office
Unit A8, 2A Westall Road
Hallmarc Business Park
Clayton VIC 3168
Australia
T: +61 3 9002 5000
E: info@avecho.com.au
Questions welcome via
our InvestorHub platform.
Share your feedback
Discover